Evolution of systemic therapy for advanced pancreatic cancer.

@article{Renouf2010EvolutionOS,
  title={Evolution of systemic therapy for advanced pancreatic cancer.},
  author={Daniel John Renouf and Malcolm J. Moore},
  journal={Expert review of anticancer therapy},
  year={2010},
  volume={10 4},
  pages={529-40}
}
The prognosis for advanced pancreatic cancer remains poor and successful drug development in this disease continues to be a major challenge. In the last decade the approach to drug development in pancreatic cancer has included a focus on combinations of cytotoxic agents. While some promising results were seen in Phase II studies, none of the Phase III trials of cytotoxic combinations were able to demonstrate an improvement in overall survival over that seen with the single-agent gemcitabine… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 77 references

Final analysis of a randomized Phase II study of bevacizumab ( B ) and gemcitabine ( G ) plus cetuximab ( C ) or erlotinib ( E ) in patients ( pts ) with advanced pancreatic cancer ( PC )

  • HL Kindler, T Gangadhar, T Karrison
  • J . Clin . Oncol .
  • 2008
Highly Influential
1 Excerpt

Phase III study of gemcitabine [ G ] plus cetuximab [ C ] versus gemcitabine in patients [ pts ] with locally advanced or metastatic pancreatic adenocarcinoma [ PC ] : SWOG S 0205 study

  • P Philip, J Benedetti, C Fenoglio-Preiser
  • J . Clin . Oncol .
  • 2007
Highly Influential
1 Excerpt

The relationship of Kras mutations and EGFR gene copy number to outcome in patients treated with erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA . 3

  • MJ Moore, G daCunhaSantos, S Kamel-Reid
  • J . Clin . Oncol .
  • 2007
Highly Influential
1 Excerpt

Association of progression - free survival , overall survival , and patientreported outcomes by skin toxicity and KRAS status in patients receiving panitumumab monotherapy

  • M Peeters, S Siena, E VanCutsem
  • Cancer
  • 2009

Similar Papers

Loading similar papers…